Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | GLI1 | P08151 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 6/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.30 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.30 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14743621 | 0.83 | SCN4A (0.40) | SCN4AGLI1SCN9ASCN3ASCN5A | |
| SCHEMBL7420310 | 0.83 | SCN4A (0.43) | SCN4AGLI1SCN9ASCN3ASCN5A | |
| SCHEMBL14743892 | 0.83 | SCN4A (0.40) | SCN4AGLI1SCN9ASCN3ASCN5A | |
| SCHEMBL24074316 | 0.78 | SCN4A (0.35) | SCN4AGLI1SCN9ASCN3ASCN5A | |
| SCHEMBL7746797 | 0.77 | SCN4A (0.36) | SCN4AGLI1SCN9ASCN3ASCN5A | |
| SCHEMBL248746 | 0.76 | NOS2 (0.39) | SCN4AGLI1SCN9ASCN3ASCN5A | |
| SCHEMBL248747 | 0.76 | NOS2 (0.39) | SCN4AGLI1SCN9ASCN3ASCN5A | |
| SCHEMBL40093 | 0.76 | NOS2 (0.39) | SCN4AGLI1SCN9ASCN3ASCN5A | |
| SCHEMBL2804278 | 0.76 | SCN9A (0.39) | SCN4ASCN9ASCN3ASCN5ADPP4 | |
| SCHEMBL6535567 | 0.76 | SCN4A (0.45) | SCN4ASCN9ASCN3ASCN5ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | disclosed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | disclosed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | SCN4A 4652/4885GLI1 3630/4885SCN9A 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.